Navigation Links
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Date:4/28/2009

    FDA confirms durable pain palliation as an acceptable primary endpoint
    for a regulatory submission in support of market approval

BOTHELL, WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a second Phase 3 registration trial of OGX-011, its lead product candidate targeting castrate resistant prostate cancer (CRPC), via the Special Protocol Assessment (SPA) process. The FDA has agreed that the design and planned analysis of our Phase 3 trial featuring durable pain palliation as the primary endpoint adequately addresses the objectives necessary to support a regulatory submission.

"We have now received confirmations on two separate Phase 3 trial designs from the FDA via the SPA process, each in second-line treatment of advanced prostate cancer," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "One trial design evaluates overall survival benefit while the second trial design evaluates reduction in pain as the primary endpoint. Having evaluated both of these endpoints in our Phase 2 trials, we are well positioned to re-evaluate each of these endpoints in larger Phase 3 registration trials."

"The FDA's acknowledgement of pain in addition to survival as key endpoints for market approval supports the basis of our OGX-011 development program for advanced prostate cancer," added Cormack. "Although we observed a positive effect on PSA in our Phase 2 trials of OGX-011, we recognize that PSA response has not been shown to correlate to a clinical benefit and therefore is not an acceptable endpoint for FDA approval. Our focus remains on survival and pain palliation, both endpoints that FDA has confirmed are appropriate for marketing approval, and both endp
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/10/2014)... 2014 Understanding the need for better ... and the gap that currently exists in this area, ... industry-leading portfolio of validated ion channel and GPCR cell ... lines, as ion channels control many critical physiological functions ... creates the potential to treat a variety of human ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... important to the economic growth of a municipality as ... viewed as transportation - rail, waterways, and air as ... definition of infrastructure must also include network infrastructure and ... , ,Just as you would not locate your company ...
... - Assembly Speaker Mike Huebsch , R-West Salem, ... named eight legislators to serve on the Speaker's Task Force ... charged with exploring a number of failed information technology projects ... public and private sectors. , ,In addition to Montgomery, who ...
... year's Biotechnology Industry Organization convention in Chicago, it wasn't ... While Chicago is a business leader in almost every ... its biotech. Pharmaceutical companies, yes; biotech firms, not really. ... so hopped up on biotech research, investors, and boom-time ...
Cached Biology Technology:States need to be more "connectivity conscious" 2States need to be more "connectivity conscious" 3States need to be more "connectivity conscious" 4Eight lawmakers named to Speaker's IT task force 2Getting noticed in Genetown: Wisconsin biotech on display 2Getting noticed in Genetown: Wisconsin biotech on display 3Getting noticed in Genetown: Wisconsin biotech on display 4
(Date:7/11/2014)... 11, 2014--Researchers at the Department of Energy,s Oak ... awards, presented by R&D Magazine in recognition of ... awards recognize the tremendous value of our National ... and development at the National Labs continues to ... pursue the scientific and technological innovations necessary to ...
(Date:7/11/2014)... BostonThe American Society for Bone and Mineral Research awarded ... of Medicine (BUSM), with the 2014 Louis V. Avioli ... at BUSM, is internationally known for revolutionizing the understanding ... , The award honors a member of the ... fundamental contributions to bone and mineral basic research. It ...
(Date:7/11/2014)... Stem Cell scientists have set a "mouse TRAP" to ... by a recent study published in the Journal ... uses a technique called TRAP to extract cellular and ... Invented by scientists at the Rockefeller Institute for Medical ... to the protein-making machinery, or ribosomes, of the cell ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... RIVERSIDE, Calif. Humans are conducting massive experiments on ... introducing exotic species, boosting nutrient concentrations, and altering climates. ... will give the Jane Block Distinguished Lecture in ... which he will discuss how our ability to assess ...
... May 7, 2013 /PRNewswire-iReach/ -- Glutathione is the ... oxidants and a large variety of other toxins and insults. ... enhancing glutathione levels in cells and tissues has simmered for ... oral supplementation is effective in increasing the body,s stores of ...
... For plants and animals forced to tough out harsh ... country is a refuge, a stable beneath-the-snow habitat that gives ... in a warming world, winter and spring snow cover in ... plants and animals that depend on the space beneath the ...
Cached Biology News:Public lecture at UC Riverside to discuss challenges in assessing human impact on ecosystems 2Clinical Tests Demonstrate Long-Term Effectiveness of Oral Glutathione Supplements - Kyowa Study 2Clinical Tests Demonstrate Long-Term Effectiveness of Oral Glutathione Supplements - Kyowa Study 3Decline in snow cover spells trouble for many plants, animals 2Decline in snow cover spells trouble for many plants, animals 3
ANTI S. ENT TOX BC2D...
... Anti-Major DNA-binding protein(DBP). Protein ... NP_001343 ELISA titre using ... Suggested conditions for Western Blot: ... buffer, and HRP conjugated anti-Rabbit IgG should ...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Biology Products: